150 results on '"Höfner, Thomas"'
Search Results
2. Radical cystectomy in patients aged < 80 years versus ≥ 80 years: analysis of preoperative geriatric assessment scores in predicting postoperative morbidity and mortality
3. Value of perilesional biopsies in multiparametric magnetic resonance imaging-targeted biopsy and systematic biopsy in detection of prostate cancer: results of a prospective, non-randomized, surgeon-blinded study
4. Individualized center-based analysis of urinary and sexual functional outcome after radical prostatectomy based on the prostate cancer outcome study: a post hoc pathway to patient outcome measurement analysis for quality improvement
5. Author reply on the Letter to the Editor on “Standardized reports of focal-HIFU results is paramount: a closer look at the Duwe et al.’s cohort on focal HIFU for localized prostate cancer”
6. ASO Visual Abstract: Temporal Trends in Urinary Diversion Among Patients Undergoing Radical Cystectomy Between 1986 and 2022: Experience at the University Medical Center Mainz with 2224 Cases
7. Einsatz neuer Technologien: Künstliche Intelligenz in der medizinischen Entscheidungsfindung – Status quo und Perspektiven einer interdisziplinären Herausforderung
8. Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study
9. Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected
10. Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequences
11. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
12. Variation across operating sites in urinary and sexual outcomes after radical prostatectomy in localized and locally advanced prostate cancer
13. Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study
14. Potential Candidates for Focal Therapy in Prostate Cancer in the Era of Magnetic Resonance Imaging–targeted Biopsy: A Large Multicenter Cohort Study
15. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
16. Global change of surgical and oncological clinical practice in urology during early COVID-19 pandemic
17. Stage and Grade Migration in Prostate Cancer Treated With Radical Prostatectomy in a Large German Multicenter Cohort
18. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer
19. Challenges and perspectives in use of artificial intelligence to support treatment recommendations in clinical oncology.
20. Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany
21. Nationwide analysis on the impact of socioeconomic land use factors and incidence of urothelial carcinoma
22. Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation
23. Efficacy of Targeted Treatment Beyond Third-Line Therapy in Metastatic Kidney Cancer: Retrospective Analysis From a Large-Volume Cancer Center
24. Defined Conditions for the Isolation and Expansion of Basal Prostate Progenitor Cells of Mouse and Human Origin
25. Solitary cardiac metastasis of urothelial carcinoma of the urinary bladder with squamous cell differentiation – a rare manifestation
26. Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort
27. V09-10 NEWLY ESTABLISHED APPROACH OF AN ENTIRELY RETROPERITONEAL ROBOTIC NEPHROURETERECTOMY
28. High–Normal Preoperative Potassium Level Is Associated with Reduced 30–Day Morbidity and Shorter Hospital Stay after Radical Cystectomy
29. Smartglass augmented reality-assisted targeted prostate biopsy using cognitive point-of-care fusion technology
30. Smartglass augmented reality‐assisted targeted prostate biopsy using cognitive point‐of‐care fusion technology
31. the Influence of Prostatic Anatomy and Neurotrophins on Basal Prostate Epithelial Progenitor Cells
32. Monoprophylaxis with cephalosporins for transrectal prostate biopsy after the fluoroquinolone-era: a multi-institutional comparison of severe infectious complications
33. Telemedicine Online Visits in Urology During the COVID-19 Pandemic—Potential, Risk Factors, and Patients’ Perspective
34. A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
35. Monoprophylaxis With Cephalosporins for Transrectal Prostate Biopsy After the Fluoroquinolone-Era: A Multi-Institutional Comparison of Severe Infectious Complications
36. Robotic surgery can be safely performed for patients and healthcare workers during COVID‐19 pandemic
37. Pandemic Spread of COVID-19 Mutant Variants Will Facilitate Next-generation Sequencing Capacities for Personalised Medicine in Urologic Oncology
38. Acceptance, Indications and Chances of Focal Therapy in Localized Prostate Cancer: A Real-World Perspective of Urologists in Germany
39. Phase 2 of the Coronavirus Pandemic in Urology: Ramping Up Surgical Caseload and Resident Training while COVID-19 Infections Decrease
40. Global change of surgical and oncological clinical practice in urology during early COVID-19 pandemic
41. The positivity rate of 68Gallium-PSMA-11 ligand PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer
42. Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice
43. Antihormonelle Therapie des Prostatakarzinoms − Behandlungsindikation und kardiovaskuläres Risikoprofil − Vorteil für GnRH-Antagonisten?
44. Antihormonelle Therapie des Prostatakarzinoms − Behandlungsindikation und kardiovaskuläres Risikoprofil − Vorteil für GnRH-Antagonisten?
45. Abstract 1063: A clear cell renal cancer metastasis model identifies novel mediators of tumor aggressiveness and predictors of patient survival
46. Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned
47. Protein profile of basal prostate epithelial progenitor cells—stage‐specific embryonal antigen 4 expressing cells have enhanced regenerative potential in vivo
48. The influence of prostatic anatomy and neurotrophins on basal prostate epithelial progenitor cells
49. Rare Case of Excessive Beta-Human Chorionic Gonadotropin Producing Intrascrotal Leiomyosarcoma: Diagnostic Pitfalls and Therapeutic Implications
50. A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.